


TAF MEK melanoma - Home - HCP

Prescribing information

Image



Image



TAFINLAR® (dabrafenib) + MEKINIST® (trametinib) in melanoma

TAFINLAR in combination with MEKINIST is indicated in adult patients with unresectable or metastatic melanoma with a *BRAF* V600 mutation.^{1,2}

TAFINLAR in combination with MEKINIST is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a *BRAF* V600 mutation, following complete resection.^{1,2}

For the full safety profile, please refer to the Summary of Product Characteristics (SmPC) for <u>TAFINLAR</u> and <u>MEKINIST</u>.

Adverse event reporting: Details of how to report adverse events are available at the bottom of the page. Please refer to the respective SmPC for all licensed indications.

Please use the buttons below to find out more about melanoma diagnosis and staging, and TAFINLAR and MEKINIST mechanism of action, efficacy, safety profile and patient management.

BRAF V600, mutation of the BRAF gene at valine (V) 600; SmPC, summary of product characteristics.

References

- 1. TAFINLAR (dabrafenib) Summary of Product Characteristics.
- 2. MEKINIST (trametinib) Summary of Product Characteristics.



Diagnosis and staging		
Diagnosis and staging		
See more details		



Mechanism of action			
Mechanism of action			
See more details			







Safety profile		
Cofe to a self-		
Safety profile		
See more details		



Management of patients with BRAF-positive melanoma	
Management of patients with BRAF-positive melanoma	
Management of patients with BRAF-positive melanoma	
See more details	

UK April 2025 FA-11217996-1
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard . Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report , or alternatively email medinfo.uk@novartis.com or call 01276 698370.
Source URL: https://www.pro.novartis.com/uk-en/medicines/oncology/tafinlar-mekinist/melanoma